IV NAD+ Therapy: What the Research Shows About Injectable and Intravenous NAD+

The short version

IV NAD+ therapy means giving NAD+ (a helper molecule cells use for energy) directly into a vein or under the skin, usually at a wellness clinic. It is not FDA-approved; it is a compounded therapy, meaning it is mixed to order rather than manufactured as an approved drug. Two facts shape the picture below. First, infused NAD+ is cleared from the blood within hours, so it does not linger the way an oral precursor's effect does. Second, the strongest human evidence in the NAD+ field comes from oral NMN and NR trials, not from IV NAD+. This page reads the route as research, with caution flags where the record warrants them — it is not an offer, a referral, or a dosing instruction.

What an IV or Injectable NAD+ Protocol Is

An NAD+ injection or infusion delivers NAD+ — or a precursor — intravenously or subcutaneously, typically as a compounded wellness therapy ^[12]. It is not FDA-approved. Reported clinic protocols use roughly 250–1000 mg per session infused slowly over several hours; one pharmacokinetic study used a 3 µmol/min continuous infusion over six hours. Infusion speed is the practical constraint: run too fast, infusions can provoke chest and abdominal discomfort, flushing and nausea. This describes documented protocols, not a recommendation.

The route exists on a spectrum the literature ranks by evidence. Oral precursors carry the bulk of controlled human data ^[4][3]; intravenous NAD+ has the weakest ^[12]; subcutaneous and intramuscular injection have minimal peer-reviewed pharmacokinetic data at all.

Pharmacokinetics: Why Infused NAD+ Clears Fast

Infused intravenous NAD+ is rapidly cleared from plasma. A pilot study found near-complete plasma removal within roughly the first two hours of infusion ^[12]. That single fact does most of the work in interpreting IV NAD+: the molecule does not establish the sustained blood-NAD+ elevation that oral precursors produce over days to weeks ^[4][3].

This is the pharmacokinetic reason controlled efficacy evidence for IV NAD+ is thin. Where rigorous human data exist in the NAD+ field, they overwhelmingly come from oral NMN and NR trials measuring blood-NAD+ elevation and metabolic endpoints ^[1][4][3], not from intravenous protocols ^[12].

Tolerability and Safety Signals in the Studies

Two safety pictures sit side by side. Oral precursors were generally well tolerated in randomized trials, with no serious adverse events at the doses tested — NR up to 1000 mg/day for 8 weeks and NMN across multi-week dosing showed no significant adverse-event difference from placebo ^[4][3]. The injectable route is different. In a real-world IV comparison, infusion-related symptoms — gastrointestinal discomfort, chest pressure and elevated heart rate — tracked infusion speed and resolved on completing the infusion.

The most concrete IV-specific risk is product quality. Compounded injectable NAD+ carries a contamination risk, and the FDA has issued a Class I recall of a compounded NAD+ injection over elevated bacterial endotoxin. A Class I recall is the agency's most serious category — the one used when a product could cause serious injury. This is why the route is read here as an unapproved compounded therapy with documented quality limits, never as an approved treatment.

Stability compounds the concern. NAD+ is hygroscopic and degrades with heat and moisture; reconstituted injectable NAD+ must be kept cold and protected from light. An injectable that is mixed to order, rather than manufactured under approved-drug controls, depends entirely on the compounder's process for sterility and accurate content — which is exactly what the endotoxin recall illustrates.

Why "Compounded" and "Approved" Are Not the Same

An FDA-approved drug has cleared review for safety, efficacy, manufacturing quality and labeling for a specific indication. A compounded preparation has not — it is mixed by a pharmacy for a particular purpose, outside that approval framework. IV and injectable NAD+ fall in the compounded category, which is why no "approved NAD+ injection" exists to point to ^[12].

This distinction is the whole reason this digest reads IV NAD+ as research rather than as a treatment. The marketing language around NAD+ infusions often borrows the confidence of approved medicine; the evidence does not support that framing. The controlled human data establishing that NAD+ can be raised at all come from oral precursor trials ^[4][3][1], and the one rigorous pharmacokinetic look at infused NAD+ showed it clears plasma within hours ^[12]. Nothing here is an endorsement of, or a referral to, any infusion service.

How the IV Route Has Been Studied

The controlled evidence for IV NAD+ is thin and mostly pilot-scale ^[12]. The one rigorous look at its pharmacokinetics used a continuous infusion (a 3 µmol/min rate over six hours) and found infused NAD+ largely cleared from plasma within roughly the first two hours ^[12]. Beyond pharmacokinetics, the published IV record is dominated by retrospective and observational reports rather than randomized, placebo-controlled trials — which is the level of evidence that exists for the oral precursors ^[4][3][1].

This is the central asymmetry of the field: the route with the most aggressive marketing has the least controlled efficacy data, while the unglamorous oral-capsule route carries the randomized trials ^[12][4]. A reader weighing IV NAD+ should know that the case for it rests largely on mechanism and anecdote, not on the kind of trial that established blood-NAD+ elevation for NMN and NR ^[4][3].

Does NAD IV Actually Work?

IV NAD+ is marketed widely but rests on minimal controlled evidence, and a pilot study found infused NAD+ is largely cleared from plasma within hours ^[12]. The robust human efficacy signals in this field — improved muscle insulin sensitivity, raised blood NAD+, better aerobic capacity — come from oral precursor trials, not from IV NAD+ ^[1][4][7]. So any value judgement about IV NAD+ sits outside what the controlled research currently establishes.